A Phase 2, Double-Blind, Placebo-Controlled Study of NSI-189, a Neurogenic Compound Among Out-Patients With Major Depressive Disorder
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs NSI 189 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Neuralstem
- 08 Aug 2017 According to a Neuralstem media release, the company will continue to data from this trial and provide a full update in the fourth quarter of 2017.
- 25 Jul 2017 Results published in a Neuralstem Media Release.
- 25 Jul 2017 Primary endpoint has not been met. (Montgomery-Asberg Depression Rating Scale (MADRS)), according to a Neuralstem media release.